CYNTHIA GUZMAN: Open Payments
NPI 1083355242 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,904 in 144 payments from 18 companies in 2025. Trend: 2023 $3,439 · 2024 $3,991 · 2025 $3,904
Food & beverage: $3,805Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $774 |
| Madrigal Pharmaceuticals | 11 | $650 |
| Janssen Biotech, Inc. | 22 | $466 |
| Lilly USA, LLC | 11 | $415 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $319 |
| Phathom Pharmaceuticals, Inc. | 6 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $209 |
| Ardelyx, Inc. | 10 | $182 |
| PFIZER INC. | 10 | $181 |
| Celltrion USA Inc. | 5 | $113 |
Products named: REZDIFFRA, TREMFYA, OMVOH, LINZESS, XIFAXAN, VOQUEZNA, IBSRELA, CREON.
Industry payments across TX — which companies pay providers there.
